(Q34240955)

31 July 2017

1 reference

title

Pharmacotherapeutic management of autism (English)

1 reference

31 July 2017

0 references

Posey DJ

1

1 reference

31 July 2017

McDougle CJ

series ordinal

2

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

Expert Opinion on Pharmacotherapy

31 July 2017

published in

1 reference

31 July 2017

volume

2

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

587-600

1 reference

The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

Case study: risperidone treatment of children and adolescents with developmental disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

An open trial of risperidone in young autistic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

Paediatric uses of atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

A pilot study of clomipramine in young autistic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

Fluoxetine Treatment of Children and Adults with Autistic Disorder and Mental Retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

Use of methylphenidate in the treatment of children with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

Naltrexone in autistic children: behavioral symptoms and attentional learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

Placebo-controlled acute dosage naltrexone study in young autistic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

Autism and Clostridium tetani

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

Short-term benefit from oral vancomycin treatment of regressive-onset autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.4.587

21 January 2018

Identifiers

DOI

10.1517/14656566.2.4.587

1 reference

31 July 2017

1 reference